08:08 AM EST, 02/25/2025 (MT Newswires) -- Beam Therapeutics ( BEAM ) reported a Q4 loss Tuesday of $1.09 per diluted share, swinging from a profit of $1.73 a year earlier.

Analysts polled by FactSet expected a loss of $1.23.

License and collaboration revenue for the quarter ended Dec. 31 was $30.1 million, down from $316.2 million a year earlier.

Analysts surveyed by FactSet expected $17.2 million.

As of Dec. 31, 2024, cash, cash equivalents and marketable securities were $850.7 million, compared with $1.2 billion a year earlier.